Scarica l'app Stockscreener
5.56
0.36%
-0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.58
Aprire:
$5.46
Volume 24 ore:
811.62K
Relative Volume:
0.49
Capitalizzazione di mercato:
$1.14B
Reddito:
-
Utile/perdita netta:
$-118.84M
Rapporto P/E:
-10.40
EPS:
-0.5344
Flusso di cassa netto:
$-101.06M
1 W Prestazione:
+5.90%
1M Prestazione:
-7.49%
6M Prestazione:
+59.31%
1 anno Prestazione:
+84.72%
Intervallo 1D:
$5.45
$5.6962
Intervallo di 1 settimana:
$4.85
$5.70
Portata 52W:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Nome
Savara Inc
Settore
Industria
Telefono
51285113796
Indirizzo
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.56 | 1.14B | 0 | -118.84M | -101.06M | -0.5344 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-11-13 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-11-07 | Iniziato | Guggenheim | Buy |
| 2023-05-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2021-03-16 | Iniziato | Piper Sandler | Overweight |
| 2021-03-15 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-13 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Ripresa | ROTH Capital | Neutral |
| 2018-01-03 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-09-27 | Ripresa | ROTH Capital | Buy |
| 2017-09-22 | Iniziato | Jefferies | Buy |
| 2017-09-11 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Savara Inc Borsa (SVRA) Ultime notizie
SVRA Technical Analysis & Stock Price Forecast - Intellectia AI
Savara Inc. (SVRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SVRA Stock Price, Quote & Chart | SAVARA INC (NASDAQ:SVRA) - ChartMill
Why Savara (SVRA) Is Up 5.7% After EMA Validates MOLBREEVI Application And FDA Priority Review - simplywall.st
Guggenheim Keeps Their Buy Rating on Savara (SVRA) - The Globe and Mail
Citizens reiterates Savara stock rating on regulatory progress By Investing.com - Investing.com Canada
Citizens reiterates Savara stock rating on regulatory progress - Investing.com
EMA validates Savara’s MOLBREEVI application for autoimmune PAP By Investing.com - Investing.com South Africa
Savara (SVRA) MAA Submission in Europe Receives Validation - GuruFocus
Jefferies reiterates Savara stock Buy rating on approval confidence By Investing.com - Investing.com India
Jefferies sees Savara stock approval odds at 90% for rare lung drug - Investing.com Canada
Jefferies reiterates Savara stock Buy rating on approval confidence - Investing.com UK
Jefferies sees Savara stock approval odds at 90% for rare lung drug By Investing.com - Investing.com South Africa
Savara reports 2025 results, advances MOLBREEVI toward approval - MSN
Savara : Corporate Presentation - marketscreener.com
Savara Inc announced that its Marketing Authorization Application (MAA) for Molbreevi*, a treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), has been formally validated by the European Medicines Agency (EMA). - Bitget
EMA validates Savara’s MOLBREEVI application for autoimmune PAP - Investing.com
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Savara grants inducement equity awards to new employee - msn.com
Death Cross: Whats the fair value of Savara Inc stockTrade Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn
High Growth Tech Stocks To Watch In The US March 2026 - Sahm
Savara (SVRA) to Release Earnings on Tuesday - MarketBeat
Savara’s MOLBREEVI BLA Receives FDA Priority Review - msn.com
FDA to review Savara resubmitted Molbreevi BLA - MSN
Savara Reports 2025 Results, Advances MOLBREEVI Toward Approval - MyChesCo
Savara Inc devrait afficher une perte de 12 cents par actionEarnings AVANT-PAPIER - TradingView
Aug Big Picture: What is the Moat Score of Savara IncNew Guidance & Stock Market Timing Techniques - baoquankhu1.vn
Savara (SVRA) CFO exercises stock options and ends with 536,032 shares - Stock Titan
VR Adviser Adds Over 1 Million Savara Shares - AOL.com
Will Advancing MOLBREEVI and a New HQ Lease Change Savara's (SVRA) Narrative? - simplywall.st
Weekly Earnings: Can Savara Inc withstand a market correctionGDP Growth & Proven Capital Preservation Tips - baoquankhu1.vn
FY2026 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat
Lifesci Capital Analysts Lift Earnings Estimates for Savara - MarketBeat
HC Wainwright Comments on Savara's Q1 Earnings (NASDAQ:SVRA) - MarketBeat
Savara Inc Azioni (SVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):